Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Van Blarcom

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal for Immunotherapy of Cancer|October 2, 2021
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunityShih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 2, 2018
Epitope Mapping Using Yeast Display and Next Generation SequencingThomas Van Blarcom, Andrea Rossi, Davide Foletti, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2025
Epitope Mapping Using Yeast Display and Next Generation SequencingThomas Van Blarcom, Andrea Rossi, Davide Foletti, et al.
Journal of Molecular Biology|July 27, 2011
Synthetic antibodies designed on natural sequence landscapesWenwu Zhai, Jacob Glanville, Markus Fuhrmann, et al.
Journal of Molecular Biology|October 7, 2014
Precise and efficient antibody epitope determination through library design, yeast display and next-generation sequencingThomas Van Blarcom, Andrea Rossi, Davide Foletti, et al.
Cancer Research|March 16, 2022
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell CarcinomaSiler H Panowski, Surabhi Srinivasan, Nguyen Tan, et al.
Scientific Reports|June 12, 2019
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Scientific Reports|November 9, 2019
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Mabs|December 12, 2017
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodiesThomas Van Blarcom, Kevin Lindquist, Zea Melton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2019
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple MyelomaCesar Sommer, Bijan Boldajipour, Tracy C Kuo, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal for Immunotherapy of Cancer|October 2, 2021
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunityShih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 2, 2018
Epitope Mapping Using Yeast Display and Next Generation SequencingThomas Van Blarcom, Andrea Rossi, Davide Foletti, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2025
Epitope Mapping Using Yeast Display and Next Generation SequencingThomas Van Blarcom, Andrea Rossi, Davide Foletti, et al.
Journal of Molecular Biology|July 27, 2011
Synthetic antibodies designed on natural sequence landscapesWenwu Zhai, Jacob Glanville, Markus Fuhrmann, et al.
Journal of Molecular Biology|October 7, 2014
Precise and efficient antibody epitope determination through library design, yeast display and next-generation sequencingThomas Van Blarcom, Andrea Rossi, Davide Foletti, et al.
Cancer Research|March 16, 2022
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell CarcinomaSiler H Panowski, Surabhi Srinivasan, Nguyen Tan, et al.
Scientific Reports|June 12, 2019
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Scientific Reports|November 9, 2019
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Mabs|December 12, 2017
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodiesThomas Van Blarcom, Kevin Lindquist, Zea Melton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2019
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple MyelomaCesar Sommer, Bijan Boldajipour, Tracy C Kuo, et al.
Pageof 2